Medtec has released a statement addressing the abnormal fluctuations in its stock trading, highlighting that the cumulative deviation in its stock's closing price over two consecutive trading days has surged to 30%. The company has noticed that the concept of 'glass substrates' has garnered significant attention in the capital market recently, leading to a notable uptick in activity within the relevant sector in the secondary market. By 2025, the sales revenue generated from Medtec's glass substrate-related products for semiconductors is projected to constitute approximately 2% of the company's total revenue. This proportion is relatively modest and is not anticipated to exert a substantial influence on the company's overall performance.
